Survodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative review
Clicks: 1
ID: 311485
2024
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #117 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The global increase in type 2 diabetes mellitus (T2DM) and obesity requires effective treatments. However, conventional antidiabetic drugs often result in weight gain, highlighting the need for novel therapies that treat both T2DM and obesity. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs have been shown to be effective in weight loss and metabolic improvement. Survodutide (BI 456906) is an investigational long-acting double agonist administered weekly. Phase 2 trials exhibited significant reductions in HbA1c (up to 1.7% at 16 weeks) and substantial weight loss (up to 14.9% at 46 weeks) in patients with T2DM and obesity. In addition, survodutide enhanced cardiovascular risk factors and some markers of non-alcoholic steatohepatitis (NASH). However, notable rates of gastrointestinal side effects and treatment discontinuation have been observed. Future research should prioritize addressing these adverse effects and assessing long-term outcomes. The current review evaluated the efficacy and safety of survodutide, a novel dual GLP-1/GIP receptor agonist, in managing obesity and T2DM. Clinical and preclinical data on survodutide were analyzed, focusing on its mechanism of action, clinical trial results, and comparisons with other therapies.
| Reference Key |
yousif2024survodutide
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Abdelmoneim B. Yousif, Ebtihal Abdelmoneim Hassan, Mohamed Fawzi Mudarres, Musaab Fahmi Yousef |
| Journal | Yemen Journal of Medicine |
| Year | 2024 |
| DOI |
10.18231/j.yjom.2024.005
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.